flecainide has been researched along with Cardiac Complex, Premature in 45 studies
Flecainide: A potent anti-arrhythmia agent, effective in a wide range of ventricular and atrial ARRHYTHMIAS and TACHYCARDIAS.
flecainide : A monocarboxylic acid amide obtained by formal condensation of the carboxy group of 2,5-bis(2,2,2-trifluoroethoxy)benzoic acid with the primary amino group of piperidin-2-ylmethylamine. An antiarrhythmic agent used (in the form of its acetate salt) to prevent and treat tachyarrhythmia (abnormal fast rhythm of the heart).
| Excerpt | Relevance | Reference |
|---|---|---|
| "This report examines whether in the Cardiac Arrhythmia Suppression Trial death and cardiac arrest from encainide, flecainide and moricizine during the titration phase and from encainide and flecainide during the follow-up phase were related to presence (Q-wave acute myocardial infarction [Q-AMI]) or absence (non-Q-AMI) of pathologic Q waves." | 9.07 | Increased risk of death and cardiac arrest from encainide and flecainide in patients after non-Q-wave acute myocardial infarction in the Cardiac Arrhythmia Suppression Trial. CAST Investigators. ( Akiyama, T; Greenberg, H; Kuo, CS; Pawitan, Y; Reynolds-Haertle, RA, 1991) |
| " The Cardiac Arrhythmia Suppression Trial (CAST) is evaluating the effect of antiarrhythmic therapy (encainide, flecainide, or moricizine) in patients with asymptomatic or mildly symptomatic ventricular arrhythmia (six or more ventricular premature beats per hour) after myocardial infarction." | 9.06 | Preliminary report: effect of encainide and flecainide on mortality in a randomized trial of arrhythmia suppression after myocardial infarction. ( , 1989) |
| "In 12 patients with coronary artery disease, 11 of them with previous myocardial infarction, the antiarrhythmic effects of orally administered flecainide (F." | 9.05 | [Antiarrhythmic efficacy of mexiletine, propafenone and flecainide in ventricular premature beats. A comparative study in patients after myocardial infarction (author's transl)]. ( Fabry, E; Klempt, HW; Nayebagha, A, 1982) |
| " We observed the appearance of ventricular tachycardia with an unusual sinusoidal QRS complex in three of five such patients treated with flecainide acetate, 200 mg twice daily." | 7.67 | Sinusoidal ventricular tachycardia associated with flecainide acetate. ( DiMarco, JP; Sellers, TD, 1984) |
| "After an initial pilot study in five patients, the effect of flecainide on chronic ventricular arrhythmias was tested during 48-hour oral administration of 250 mg twice a day in nine further patients with previously drug-resistant chronic, stable ventricular arrhythmias." | 7.66 | [Effect of flecainide on chronic ventricular arrhythmias (author's transl)]. ( Abendroth, RR; Bluschke, V; Breithardt, G; Seipel, L, 1982) |
| "For single ventricular extrasystoles, doublets and triplets, nine very good results (80 to 100 per cent reduction of arrhythmia) and four 50 to 80 per cent reductions in ventricular prematurity were obtained." | 5.27 | [Study of flecainide in the treatment of ventricular arrhythmia]. ( Errera, J; Hug, C; Koliopoulos, N; Puech, P; Tardy, C, 1983) |
| "Encainide, flecainide and moricizine all caused a decrease in RR variability in patients studied approximately 1 month after acute myocardial infarction." | 5.07 | Predicting mortality after myocardial infarction from the response of RR variability to antiarrhythmic drug therapy. ( Bigger, JT; Fleiss, JL; Rolnitzky, LM; Steinman, RC, 1994) |
| "This report examines whether in the Cardiac Arrhythmia Suppression Trial death and cardiac arrest from encainide, flecainide and moricizine during the titration phase and from encainide and flecainide during the follow-up phase were related to presence (Q-wave acute myocardial infarction [Q-AMI]) or absence (non-Q-AMI) of pathologic Q waves." | 5.07 | Increased risk of death and cardiac arrest from encainide and flecainide in patients after non-Q-wave acute myocardial infarction in the Cardiac Arrhythmia Suppression Trial. CAST Investigators. ( Akiyama, T; Greenberg, H; Kuo, CS; Pawitan, Y; Reynolds-Haertle, RA, 1991) |
| "Moricizine was studied in 908 patients with ventricular arrhythmias." | 5.06 | Proarrhythmic potential of moricizine: strengths and limitations of a data base analysis. ( Pratt, CM, 1990) |
| " The Cardiac Arrhythmia Suppression Trial (CAST) is evaluating the effect of antiarrhythmic therapy (encainide, flecainide, or moricizine) in patients with asymptomatic or mildly symptomatic ventricular arrhythmia (six or more ventricular premature beats per hour) after myocardial infarction." | 5.06 | Preliminary report: effect of encainide and flecainide on mortality in a randomized trial of arrhythmia suppression after myocardial infarction. ( , 1989) |
| "In 12 patients with coronary artery disease, 11 of them with previous myocardial infarction, the antiarrhythmic effects of orally administered flecainide (F." | 5.05 | [Antiarrhythmic efficacy of mexiletine, propafenone and flecainide in ventricular premature beats. A comparative study in patients after myocardial infarction (author's transl)]. ( Fabry, E; Klempt, HW; Nayebagha, A, 1982) |
| " In patients refractory to amiodarone alone or to a combination with mexiletine, the combined treatment with amiodarone and class-I-C drugs such as flecainide and encainide prolongs the cycle length of ventricular tachycardia, but does not suppress induction of ventricular tachycardia during programmed stimulation." | 3.68 | [Combination anti-arrhythmic drug therapy]. ( Jung, W; Lüderitz, B; Manz, M, 1992) |
| " We observed the appearance of ventricular tachycardia with an unusual sinusoidal QRS complex in three of five such patients treated with flecainide acetate, 200 mg twice daily." | 3.67 | Sinusoidal ventricular tachycardia associated with flecainide acetate. ( DiMarco, JP; Sellers, TD, 1984) |
| "After an initial pilot study in five patients, the effect of flecainide on chronic ventricular arrhythmias was tested during 48-hour oral administration of 250 mg twice a day in nine further patients with previously drug-resistant chronic, stable ventricular arrhythmias." | 3.66 | [Effect of flecainide on chronic ventricular arrhythmias (author's transl)]. ( Abendroth, RR; Bluschke, V; Breithardt, G; Seipel, L, 1982) |
| " 2,5-Bis-(2,2,2-trifluoroethoxy)-N-(2-piperidylmethyl)benzamide acetate (flecainide, R 818, Tambocor) caused a significant increase of the atrial and ventricular fibrillation thresholds." | 3.66 | Effects of flecainide on atrial and ventricular stimulation thresholds to repetitive extrasystoles and fibrillation and on "2nd Phase" ventricular arrhythmias in dogs. ( Bender, F; Gülker, H; Heuer, H; Thale, J, 1983) |
| "The Elimination of Ventricular Premature Beats with Catheter Ablation versus Optimal Antiarrhythmic Drug Treatment (ECTOPIA) trial is a randomized, multicenter, prospective clinical trial to compare the efficacy of catheter ablation versus optimal AAD treatment with sotalol or flecainide/verapamil." | 2.94 | Elimination of Benign Ventricular Premature Beats or Ventricular Tachycardia with Catheter Ablation versus Two Different Optimal Antiarrhythmic Drug Treatment Regimens (Sotalol or Verapamil/Flecainide). ( Adiyaman, A; Beukema, RJ; de Jong, JSSG; Delnoy, PPHM; Elvan, A; Haanschoten, DM; Khan, M; Otten, AM; Ramdat Misier, AR; Smit, JJJ; Szili-Torok, T; Ter Bekke, RMA; Vernooy, K, 2020) |
| "The short QT syndrome is characterized by familial sudden death, short refractory periods, and inducible ventricular fibrillation." | 2.71 | Short QT Syndrome: a familial cause of sudden death. ( Bianchi, F; Borggrefe, M; Gaita, F; Giustetto, C; Grossi, S; Riccardi, R; Richiardi, E; Schimpf, R; Wolpert, C, 2003) |
| "Flecainide was superior to mexiletine in overall PVC reduction (p less than 0." | 2.67 | A double-blind crossover comparison of flecainide and slow-release mexiletine in the treatment of stable premature ventricular complexes. ( Balducelli, M; Boriani, G; Capucci, A; Carini, G; Carozzi, A; Di Pasquale, G; Finzi, A; Frabetti, L; Magnani, B; Pinelli, G, 1991) |
| "There were 63 deaths/resuscitated cardiac arrests in the active treatment (encainide/flecainide) group and 26 in the placebo group." | 2.67 | Prevalence, characteristics and significance of ventricular premature complexes and ventricular tachycardia detected by 24-hour continuous electrocardiographic recording in the Cardiac Arrhythmia Suppression Trial. CAST Investigators. ( Denes, P; Gillis, AM; Kammerling, JM; Pawitan, Y; Salerno, DM; Wilhelmsen, L, 1991) |
| "Flecainide was given in a dose of 200 mg twice daily." | 2.66 | Evaluation of the efficacy of flecainide acetate in the treatment of ventricular premature contractions. ( Camm, AJ; Hellestrand, K; Muhiddin, KA; Turner, P, 1985) |
| "Only flecainide was active against VES (-88." | 2.65 | [Comparative study of a slow-release quinidine preparation and flecainide administered in 2 daily doses for the treatment of extrasystole]. ( Bricaud, H; Castagne, D; Clémenty, J; Dallocchio, M, 1984) |
| "Current management of ventricular arrhythmias are considered in the light of these findings." | 2.38 | Treatment of ventricular arrhythmias after CAST. ( Tonkin, AM, 1992) |
| "Amiodarone was also more beneficial than individual antiarrhythmic therapy (mortality 10/100 patients, 10%)." | 2.38 | [What is the latest in anti-arrhythmia therapy?]. ( Gloor, HO, 1991) |
| "Tachycardia was observed in 15% of cases (three cases of supraventricular tachycardia [SVT] and two cases of auricular flutter [AF])." | 1.31 | [Fetal arrhythmias: diagnosis, prognosis, treatment; apropos of 33 cases]. ( Dubos, JP; Dufour, P; Puech, F; Subtil, D; Vaast, P; Vaksmann, G; Valat, AS; Vautier-Rit, S, 2000) |
| "When examined on premature beats, AT was delayed, depending on the coupling interval and the fiber direction when saline, flecainide or lidocaine was infused." | 1.30 | Electrophysiologic effects of sodium channel blockade on anisotropic conduction and conduction block in canine myocardium: preferential slowing of longitudinal conduction by flecainide versus disopyramide or lidocaine. ( Kondo, T; Kubota, I; Tachibana, H; Tomoike, H; Yamaki, M, 1997) |
| "Flecainide acetate was administered at a dose of 100 mg twice daily to 15 patients with drug-resistant ventricular ectopy." | 1.28 | Oral flecainide for the treatment of drug-resistant ventricular ectopy. ( Sclarovsky, S; Stein, S; Strasberg, B, 1990) |
| " Daily flecainide dosage was 200 (100-400) mg." | 1.28 | Antiarrhythmic treatment with flecainide (Tambocor). Clinical experience from 107 patients. ( Frandsen, F; Mickley, H; Møller, M; Pless, P, 1990) |
| "Flecainide (F) is a new antiarrhythmic agent recently introduced into clinical practice." | 1.28 | [Kinetics of intravenously administered flecainide in patients with acute myocardial infarct]. ( Carelli, M; Di Marcotullio, G; Giampaolo, P; Malinconico, U; Milazzotto, F; Polizzi, CA; Tubaro, M, 1989) |
| "For single ventricular extrasystoles, doublets and triplets, nine very good results (80 to 100 per cent reduction of arrhythmia) and four 50 to 80 per cent reductions in ventricular prematurity were obtained." | 1.27 | [Study of flecainide in the treatment of ventricular arrhythmia]. ( Errera, J; Hug, C; Koliopoulos, N; Puech, P; Tardy, C, 1983) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 22 (48.89) | 18.7374 |
| 1990's | 17 (37.78) | 18.2507 |
| 2000's | 3 (6.67) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 3 (6.67) | 2.80 |
| Authors | Studies |
|---|---|
| Osadchii, OE | 1 |
| Sonesson, SE | 1 |
| Acharya, G | 1 |
| Haanschoten, DM | 1 |
| Vernooy, K | 1 |
| Beukema, RJ | 1 |
| Szili-Torok, T | 1 |
| Ter Bekke, RMA | 1 |
| Khan, M | 1 |
| de Jong, JSSG | 1 |
| Otten, AM | 1 |
| Adiyaman, A | 1 |
| Smit, JJJ | 1 |
| Delnoy, PPHM | 1 |
| Ramdat Misier, AR | 1 |
| Elvan, A | 1 |
| Gaita, F | 1 |
| Giustetto, C | 1 |
| Bianchi, F | 1 |
| Wolpert, C | 1 |
| Schimpf, R | 1 |
| Riccardi, R | 1 |
| Grossi, S | 1 |
| Richiardi, E | 1 |
| Borggrefe, M | 1 |
| Bramann, HU | 1 |
| Bender, F | 2 |
| Jachmann, H | 1 |
| Grosse-Heitmeyer, W | 1 |
| Bluschke, V | 1 |
| Breithardt, G | 2 |
| Abendroth, RR | 1 |
| Seipel, L | 1 |
| Klempt, HW | 1 |
| Nayebagha, A | 1 |
| Fabry, E | 1 |
| Hug, C | 1 |
| Koliopoulos, N | 1 |
| Tardy, C | 1 |
| Errera, J | 1 |
| Puech, P | 1 |
| Heuer, H | 1 |
| Gülker, H | 1 |
| Thale, J | 1 |
| Sellers, TD | 1 |
| DiMarco, JP | 1 |
| Clémenty, J | 1 |
| Castagne, D | 1 |
| Dallocchio, M | 1 |
| Bricaud, H | 1 |
| Bigger, JT | 1 |
| Rolnitzky, LM | 1 |
| Steinman, RC | 1 |
| Fleiss, JL | 1 |
| Stramba-Badiale, M | 1 |
| Lazzarotti, M | 1 |
| Facchini, M | 1 |
| Schwartz, PJ | 2 |
| Kondo, T | 1 |
| Yamaki, M | 1 |
| Kubota, I | 1 |
| Tachibana, H | 1 |
| Tomoike, H | 1 |
| Vautier-Rit, S | 1 |
| Dufour, P | 1 |
| Vaksmann, G | 1 |
| Subtil, D | 1 |
| Vaast, P | 1 |
| Valat, AS | 1 |
| Dubos, JP | 1 |
| Puech, F | 1 |
| Lombardi, F | 1 |
| Torzillo, D | 1 |
| Sandrone, G | 1 |
| Dalla Vecchia, L | 1 |
| Cappiello, E | 1 |
| Lüderitz, B | 1 |
| Jung, W | 1 |
| Manz, M | 1 |
| Tonkin, AM | 1 |
| Pratt, CM | 2 |
| Brater, DC | 1 |
| Harrell, FE | 1 |
| Kowey, PR | 1 |
| Leier, CV | 1 |
| Lowenthal, DT | 1 |
| Messerli, F | 1 |
| Packer, M | 1 |
| Pritchett, EL | 1 |
| Ruskin, JN | 1 |
| Akhtar, M | 1 |
| Camm, AJ | 2 |
| Coumel, P | 1 |
| Janse, MJ | 1 |
| Lazzara, R | 1 |
| Myerburg, RJ | 2 |
| Waldo, AL | 1 |
| Wellens, HJ | 1 |
| Wagner, X | 1 |
| Jouglard, J | 1 |
| Moulin, M | 1 |
| Miller, AM | 1 |
| Petitjean, J | 1 |
| Pisapia, A | 1 |
| Strasberg, B | 1 |
| Stein, S | 1 |
| Sclarovsky, S | 1 |
| Frandsen, F | 1 |
| Pless, P | 1 |
| Mickley, H | 1 |
| Møller, M | 1 |
| Capucci, A | 1 |
| Di Pasquale, G | 1 |
| Boriani, G | 1 |
| Carini, G | 1 |
| Balducelli, M | 1 |
| Frabetti, L | 1 |
| Carozzi, A | 1 |
| Finzi, A | 1 |
| Pinelli, G | 1 |
| Magnani, B | 1 |
| Denes, P | 1 |
| Gillis, AM | 1 |
| Pawitan, Y | 2 |
| Kammerling, JM | 1 |
| Wilhelmsen, L | 1 |
| Salerno, DM | 1 |
| Gloor, HO | 1 |
| Akiyama, T | 1 |
| Greenberg, H | 1 |
| Kuo, CS | 1 |
| Reynolds-Haertle, RA | 1 |
| Somberg, J | 1 |
| Muhiddin, KA | 1 |
| Turner, P | 1 |
| Hellestrand, K | 1 |
| Somberg, JC | 1 |
| Miura, D | 1 |
| Keefe, DL | 1 |
| Andresen, D | 1 |
| von Leitner, ER | 1 |
| Wegscheider, K | 1 |
| Theiss, A | 1 |
| Agena, H | 1 |
| Schröder, R | 1 |
| Nestico, PF | 1 |
| Morganroth, J | 1 |
| Samlowski, WE | 1 |
| Frame, RN | 1 |
| Logue, GL | 1 |
| Mangini, SG | 1 |
| Mastropasqua, F | 1 |
| Lagioia, R | 1 |
| Ricci, A | 1 |
| Scrutinio, D | 1 |
| Rizzon, P | 1 |
| Henze, E | 1 |
| Roth, J | 1 |
| Haerer, W | 1 |
| Adam, WE | 1 |
| Stauch, M | 1 |
| Greene, HL | 1 |
| Richardson, DW | 1 |
| Hallstrom, AP | 2 |
| McBride, R | 1 |
| Capone, RJ | 1 |
| Barker, AH | 2 |
| Roden, DM | 1 |
| Echt, DS | 1 |
| Anderson, JL | 1 |
| Griffith, LS | 1 |
| Ledingham, RB | 1 |
| Reiffel, JA | 1 |
| Yusuf, S | 1 |
| Fowles, RE | 1 |
| Young, JB | 1 |
| Polizzi, CA | 1 |
| Carelli, M | 1 |
| Giampaolo, P | 1 |
| Di Marcotullio, G | 1 |
| Tubaro, M | 1 |
| Malinconico, U | 1 |
| Milazzotto, F | 1 |
| Li, XY | 1 |
| Kessler, KM | 1 |
| Cox, MM | 1 |
| Huikuri, H | 1 |
| Terracall, E | 1 |
| Interian, A | 1 |
| Fernandez, P | 1 |
| Castellanos, A | 1 |
| Farré, J | 1 |
| Brugada, P | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| The Ability of Several Short-term Measures of RR Variability to Predict Mortality After Myocardial Infarction[NCT00005235] | 715 participants (Actual) | Observational | 1988-12-31 | Completed | |||
| [NCT00000526] | Phase 3 | 0 participants | Interventional | 1986-08-31 | Completed | ||
| [NCT00000504] | Phase 2 | 0 participants | Interventional | 1982-09-30 | Completed | ||
| Can Global Peak Longitudinal Strain Measurements in Combination With Non-invasive ECG Parameters Predict the Success or Failure of Flecainide Treatment for Atrial Fibrillation Patients?[NCT05084495] | 100 participants (Anticipated) | Observational | 2022-02-01 | Recruiting | |||
| Catheter Ablation for Ventricular Tachycardia in Patients With an Implantable Cardioverter Defibrillator (CALYPSO) PILOT TRIAL[NCT01576042] | 27 participants (Actual) | Interventional | 2012-05-31 | Terminated (stopped due to Main objectives of the study were met; consensus among investigators that continuing the study would not add new information beyond that already learned.) | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Records participants hospitalized for VT during the study (NCT01576042)
Timeframe: Baseline, 6 months
| Intervention | participants (Number) |
|---|---|
| Catheter Ablation | 5 |
| Antiarrhythmic Medication | 7 |
Records participants who completed Month 3 Follow-Up Visit (NCT01576042)
Timeframe: 3 months
| Intervention | participants (Number) |
|---|---|
| Catheter Ablation | 11 |
| Antiarrhythmic Medication | 12 |
Records participants who completed Month 6 Follow-Up Visit (NCT01576042)
Timeframe: 6 Months
| Intervention | participants (Number) |
|---|---|
| Catheter Ablation | 7 |
| Antiarrhythmic Medication | 10 |
Records participants who had at least one of the efficacy outcome measurement (including death, hospitalization due to VT) (NCT01576042)
Timeframe: 6 Months
| Intervention | participants (Number) |
|---|---|
| Catheter Ablation | 11 |
| Antiarrhythmic Medication | 14 |
Records participants who received study randomized treatment during the study (NCT01576042)
Timeframe: 6 months
| Intervention | participants (Number) |
|---|---|
| Catheter Ablation | 11 |
| Antiarrhythmic Medication | 14 |
Records participants who only received study treatment as randomized during the entire study (NCT01576042)
Timeframe: 6 month
| Intervention | participants (Number) |
|---|---|
| Catheter Ablation | 6 |
| Antiarrhythmic Medication | 13 |
Records participants who received study treatment as randomized and later switched to other treatment arm during the study (NCT01576042)
Timeframe: 6 months
| Intervention | participants (Number) |
|---|---|
| Catheter Ablation | 5 |
| Antiarrhythmic Medication | 1 |
Days from the date of the first study treatment to the date of first ICD recurrent therapy for VT. (NCT01576042)
Timeframe: Baseline, 6 months
| Intervention | Days (Mean) |
|---|---|
| Catheter Ablation | 70.1 |
| Antiarrhythmic Medication | 78.7 |
5 reviews available for flecainide and Cardiac Complex, Premature
| Article | Year |
|---|---|
Treatment of ventricular arrhythmias after CAST.
Topics: Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Cardiac Complexes, Premature; Clinical Trials as Topic | 1992 |
CAST and beyond. Implications of the Cardiac Arrhythmia Suppression Trial. Task Force of the Working Group on Arrhythmias of the European Society of Cardiology.
Topics: Anilides; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Cardiac Complexes, Premature; Double-Blind M | 1990 |
[What is the latest in anti-arrhythmia therapy?].
Topics: Amiodarone; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Cardiac Complexes, Premature; Clinical Tri | 1991 |
The treatment of ventricular rhythm disturbances.
Topics: Adrenergic beta-Antagonists; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Cardiac Complexes, Premat | 1986 |
[Postinfarct ventricular extrasystole and the use of anti-arrhythmic drugs: a danger anticipated by electrophysiologists].
Topics: Anti-Arrhythmia Agents; Cardiac Complexes, Premature; Death, Sudden; Electrophysiology; Flecainide; | 1989 |
18 trials available for flecainide and Cardiac Complex, Premature
| Article | Year |
|---|---|
Elimination of Benign Ventricular Premature Beats or Ventricular Tachycardia with Catheter Ablation versus Two Different Optimal Antiarrhythmic Drug Treatment Regimens (Sotalol or Verapamil/Flecainide).
Topics: Anti-Arrhythmia Agents; Cardiac Complexes, Premature; Catheter Ablation; Flecainide; Humans; Prospec | 2020 |
Short QT Syndrome: a familial cause of sudden death.
Topics: Adolescent; Adult; Aged; Arrhythmias, Cardiac; Atrial Fibrillation; Cardiac Complexes, Premature; Ch | 2003 |
[Antiarrhythmic efficacy of mexiletine, propafenone and flecainide in ventricular premature beats. A comparative study in patients after myocardial infarction (author's transl)].
Topics: Adult; Aged; Anti-Arrhythmia Agents; Cardiac Complexes, Premature; Coronary Disease; Electrocardiogr | 1982 |
[Comparative study of a slow-release quinidine preparation and flecainide administered in 2 daily doses for the treatment of extrasystole].
Topics: Adult; Aged; Anti-Arrhythmia Agents; Cardiac Complexes, Premature; Delayed-Action Preparations; Drug | 1984 |
Predicting mortality after myocardial infarction from the response of RR variability to antiarrhythmic drug therapy.
Topics: Anti-Arrhythmia Agents; Cardiac Complexes, Premature; Electrocardiography, Ambulatory; Encainide; Fe | 1994 |
Clinical and regulatory implications of the Cardiac Arrhythmia Suppression Trial.
Topics: Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Cardiac Complexes, Premature; Flecainide; Humans; Rand | 1990 |
Proarrhythmic potential of moricizine: strengths and limitations of a data base analysis.
Topics: Anilides; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Cardiac Complexes, Premature; Clinical Trial | 1990 |
CAST and beyond. Implications of the Cardiac Arrhythmia Suppression Trial. Task Force of the Working Group on Arrhythmias of the European Society of Cardiology.
Topics: Anilides; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Cardiac Complexes, Premature; Double-Blind M | 1990 |
A double-blind crossover comparison of flecainide and slow-release mexiletine in the treatment of stable premature ventricular complexes.
Topics: Cardiac Complexes, Premature; Delayed-Action Preparations; Double-Blind Method; Electrocardiography; | 1991 |
Prevalence, characteristics and significance of ventricular premature complexes and ventricular tachycardia detected by 24-hour continuous electrocardiographic recording in the Cardiac Arrhythmia Suppression Trial. CAST Investigators.
Topics: Anti-Arrhythmia Agents; Cardiac Complexes, Premature; Cross-Sectional Studies; Electric Countershock | 1991 |
Increased risk of death and cardiac arrest from encainide and flecainide in patients after non-Q-wave acute myocardial infarction in the Cardiac Arrhythmia Suppression Trial. CAST Investigators.
Topics: Cardiac Complexes, Premature; Cause of Death; Drug Combinations; Electrocardiography; Encainide; Fem | 1991 |
Evaluation of the efficacy of flecainide acetate in the treatment of ventricular premature contractions.
Topics: Adult; Aged; Anti-Arrhythmia Agents; Cardiac Complexes, Premature; Clinical Trials as Topic; Double- | 1985 |
[Comparative study of the anti-arrhythmia effect of flecainide acetate and prajmalium bitartrate in patients with tachycardiac ventricular rhythm disorders].
Topics: Adult; Aged; Ajmaline; Cardiac Complexes, Premature; Clinical Trials as Topic; Electrocardiography; | 1986 |
Long term inotropic effects of flecainide and propafenone.
Topics: Administration, Oral; Adult; Cardiac Complexes, Premature; Clinical Trials as Topic; Exercise Test; | 1988 |
Recruitment and baseline description of patients in the Cardiac Arrhythmia Pilot Study. The Cardiac Arrhythmia Pilot Study (CAPS) investigators.
Topics: Anilides; Anti-Arrhythmia Agents; Cardiac Complexes, Premature; Electrocardiography; Encainide; Feas | 1988 |
Congestive heart failure after acute myocardial infarction in patients receiving antiarrhythmic agents for ventricular premature complexes (Cardiac Arrhythmia Pilot Study).
Topics: Anilides; Anti-Arrhythmia Agents; Cardiac Complexes, Premature; Double-Blind Method; Encainide; Fema | 1989 |
Relation of baseline characteristics to suppression of ventricular arrhythmias during placebo and active antiarrhythmic therapy in patients after myocardial infarction.
Topics: Anilides; Anti-Arrhythmia Agents; Cardiac Complexes, Premature; Encainide; Flecainide; Humans; Imipr | 1989 |
Preliminary report: effect of encainide and flecainide on mortality in a randomized trial of arrhythmia suppression after myocardial infarction.
Topics: Aged; Anilides; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Cardiac Complexes, Premature; Clinical | 1989 |
Preliminary report: effect of encainide and flecainide on mortality in a randomized trial of arrhythmia suppression after myocardial infarction.
Topics: Aged; Anilides; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Cardiac Complexes, Premature; Clinical | 1989 |
Preliminary report: effect of encainide and flecainide on mortality in a randomized trial of arrhythmia suppression after myocardial infarction.
Topics: Aged; Anilides; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Cardiac Complexes, Premature; Clinical | 1989 |
Preliminary report: effect of encainide and flecainide on mortality in a randomized trial of arrhythmia suppression after myocardial infarction.
Topics: Aged; Anilides; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Cardiac Complexes, Premature; Clinical | 1989 |
Preliminary report: effect of encainide and flecainide on mortality in a randomized trial of arrhythmia suppression after myocardial infarction.
Topics: Aged; Anilides; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Cardiac Complexes, Premature; Clinical | 1989 |
Preliminary report: effect of encainide and flecainide on mortality in a randomized trial of arrhythmia suppression after myocardial infarction.
Topics: Aged; Anilides; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Cardiac Complexes, Premature; Clinical | 1989 |
Preliminary report: effect of encainide and flecainide on mortality in a randomized trial of arrhythmia suppression after myocardial infarction.
Topics: Aged; Anilides; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Cardiac Complexes, Premature; Clinical | 1989 |
Preliminary report: effect of encainide and flecainide on mortality in a randomized trial of arrhythmia suppression after myocardial infarction.
Topics: Aged; Anilides; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Cardiac Complexes, Premature; Clinical | 1989 |
Preliminary report: effect of encainide and flecainide on mortality in a randomized trial of arrhythmia suppression after myocardial infarction.
Topics: Aged; Anilides; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Cardiac Complexes, Premature; Clinical | 1989 |
23 other studies available for flecainide and Cardiac Complex, Premature
| Article | Year |
|---|---|
Antiarrhythmic drug effects on premature beats are partly determined by prior cardiac activation frequency in perfused guinea-pig heart.
Topics: Action Potentials; Animals; Anti-Arrhythmia Agents; Cardiac Complexes, Premature; Electrophysiologic | 2020 |
How to differentiate second-degree atrioventricular block from extrasystoles in fetuses with a bigeminal ventricular rhythm.
Topics: Atrioventricular Block; Cardiac Complexes, Premature; Digoxin; Female; Fetus; Flecainide; Humans; Pr | 2020 |
[Caution in therapy of ventricular extrasystole. Staying safe with electrolytes].
Topics: Anti-Arrhythmia Agents; Aspartic Acid; Cardiac Complexes, Premature; Cause of Death; Drug Combinatio | 2002 |
[Long-term therapy with flecainide].
Topics: Administration, Oral; Adolescent; Adult; Aged; Anti-Arrhythmia Agents; Cardiac Complexes, Premature; | 1984 |
[Effect of flecainide on chronic ventricular arrhythmias (author's transl)].
Topics: Adult; Anti-Arrhythmia Agents; Aortic Valve Stenosis; Arrhythmias, Cardiac; Cardiac Complexes, Prema | 1982 |
[Study of flecainide in the treatment of ventricular arrhythmia].
Topics: Adolescent; Adult; Aged; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Cardiac Complexes, Premature; | 1983 |
Effects of flecainide on atrial and ventricular stimulation thresholds to repetitive extrasystoles and fibrillation and on "2nd Phase" ventricular arrhythmias in dogs.
Topics: Animals; Anti-Arrhythmia Agents; Cardiac Complexes, Premature; Dogs; Electric Stimulation; Female; F | 1983 |
Sinusoidal ventricular tachycardia associated with flecainide acetate.
Topics: Aged; Anti-Arrhythmia Agents; Cardiac Complexes, Premature; Electrocardiography; Female; Flecainide; | 1984 |
Malignant arrhythmias and acute myocardial ischemia: interaction between flecainide and the autonomic nervous system.
Topics: Animals; Autonomic Nervous System; Cardiac Complexes, Premature; Cats; Electrocardiography; Flecaini | 1994 |
Electrophysiologic effects of sodium channel blockade on anisotropic conduction and conduction block in canine myocardium: preferential slowing of longitudinal conduction by flecainide versus disopyramide or lidocaine.
Topics: Animals; Anti-Arrhythmia Agents; Cardiac Complexes, Premature; Disopyramide; Dogs; Electric Conducti | 1997 |
[Fetal arrhythmias: diagnosis, prognosis, treatment; apropos of 33 cases].
Topics: Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Bradycardia; Cardiac Complexes, Premature; Echocardiog | 2000 |
Autonomic effects of antiarrhythmic drugs and their importance.
Topics: Adult; Autonomic Nervous System; Cardiac Complexes, Premature; Electrocardiography; Female; Flecaini | 1992 |
[Combination anti-arrhythmic drug therapy].
Topics: Amiodarone; Anti-Arrhythmia Agents; Cardiac Complexes, Premature; Drug Therapy, Combination; Electro | 1992 |
Coadministration of flecainide acetate and sotalol during pregnancy: lack of teratogenic effects, passage across the placenta, and excretion in human breast milk.
Topics: Adult; Cardiac Complexes, Premature; Drug Therapy, Combination; Female; Flecainide; Humans; Maternal | 1990 |
Oral flecainide for the treatment of drug-resistant ventricular ectopy.
Topics: Administration, Oral; Adult; Aged; Arrhythmias, Cardiac; Cardiac Complexes, Premature; Drug Evaluati | 1990 |
Antiarrhythmic treatment with flecainide (Tambocor). Clinical experience from 107 patients.
Topics: Administration, Oral; Adolescent; Adult; Aged; Aged, 80 and over; Atrial Fibrillation; Atrial Flutte | 1990 |
The spectrum of CAST I and II.
Topics: Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Cardiac Complexes, Premature; Death, Sudden, Cardiac; | 1991 |
Flecainide: a new antiarrhythmic agent.
Topics: Arrhythmias, Cardiac; Cardiac Complexes, Premature; Dizziness; Electrophysiology; Flecainide; Hemody | 1986 |
Flecanide-induced immune neutropenia. Documentation of a hapten-mediated mechanism of cell destruction.
Topics: Aged; Agranulocytosis; Binding Sites, Antibody; Cardiac Complexes, Premature; Flecainide; Haptens; H | 1987 |
[Non-invasive evaluation of the effectiveness of flecainide in the treatment of ventricular extrasystole arrhythmia].
Topics: Adult; Aged; Cardiac Complexes, Premature; Chronic Disease; Female; Flecainide; Heart Ventricles; Hu | 1986 |
[Kinetics of intravenously administered flecainide in patients with acute myocardial infarct].
Topics: Adult; Aged; Arrhythmias, Cardiac; Cardiac Complexes, Premature; Female; Flecainide; Heart Ventricle | 1989 |
[A preliminary study on oral flecainide acetate in treating tachyarrhythmias].
Topics: Aged; Aged, 80 and over; Cardiac Complexes, Premature; Coronary Disease; Electrocardiography; Feedin | 1989 |
Reversal of proarrhythmic effects of flecainide acetate and encainide hydrochloride by propranolol.
Topics: Aged; Anilides; Anti-Arrhythmia Agents; Cardiac Complexes, Premature; Cardiac Pacing, Artificial; En | 1989 |